Belpointe Asset Management LLC Trims Stock Holdings in Sanofi (NASDAQ:SNY)

Belpointe Asset Management LLC reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 5.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,023 shares of the company’s stock after selling 238 shares during the quarter. Belpointe Asset Management LLC’s holdings in Sanofi were worth $194,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. CreativeOne Wealth LLC bought a new position in shares of Sanofi in the fourth quarter valued at approximately $423,000. Mariner LLC boosted its holdings in Sanofi by 8.0% in the 4th quarter. Mariner LLC now owns 108,997 shares of the company’s stock valued at $5,257,000 after purchasing an additional 8,107 shares during the period. Barclays PLC grew its position in shares of Sanofi by 58.3% during the 4th quarter. Barclays PLC now owns 1,012,927 shares of the company’s stock valued at $48,853,000 after purchasing an additional 373,155 shares in the last quarter. SageView Advisory Group LLC bought a new position in shares of Sanofi in the fourth quarter worth $300,000. Finally, Sagespring Wealth Partners LLC bought a new position in shares of Sanofi in the fourth quarter worth $469,000. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $50.90 on Friday. The company has a market capitalization of $128.59 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.01 and a beta of 0.57. The business has a 50 day moving average of $54.79 and a 200 day moving average of $52.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a boost from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi’s dividend payout ratio (DPR) is 59.04%.

Analyst Ratings Changes

Several equities analysts recently commented on SNY shares. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, BNP Paribas began coverage on shares of Sanofi in a report on Tuesday. They issued an “outperform” rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.